AI Article Synopsis

  • A study conducted in Oman examined the link between chronic kidney disease (CKD) and viral hepatitis (HBV and HCV) in 233 patients, revealing a high prevalence of both conditions. !* -
  • Results showed that chronic HCV patients had the highest CKD prevalence (78%), while those with HBV and HCV coinfection had the lowest average kidney function (eGFR of 57.6 mL/min/1.73 m²). !* -
  • The research suggests a significant association between viral hepatitis infections and CKD risk, highlighting the need for monitoring kidney function in hepatitis patients and screening CKD patients for viral hepatitis. !*

Article Abstract

Chronic kidney disease (CKD), hepatitis B virus (HBV), and hepatitis C virus (HCV) have a high prevalence in Oman. This study aimed to examine the association between CKD and viral hepatitis through an observational cohort study conducted at the Royal Hospital of the Sultanate of Oman to evaluate the relationship of HBV and HCV with CKD. During the study, 233 patients were identified, 112 with chronic HBV (Group 1), 112 with chronic HCV (Group 2), and nine with HBV and HCV coinfection (Group 3). The population was predominantly male, especially in Groups 1 and 3. The difference in age between Groups 1 and 2 was significant, with the mean age being 48 ± 14.6 years and 55 ± 12.6 years, respectively (P <0.05). This study revealed that the prevalence of CKD in Group 1 is 51%, in Group 2 was 78%, and in Group 3 was 56%. The mean estimated glomerular filtration rate (eGFR) was 79.7 mL/min/1.73 m in Group 1, 73.2 mL/min/1.73 m in Group 2, and 57.6 mL/min/1.73 m in Group 3. CKD had the highest prevalence in Group 2. The lowest eGFR was found in Group 3. Group 2 showed the highest rate of declining renal function over time despite treatment. This study found a significant and independent association between viral hepatitis and the risk of CKD, especially in cases of coinfection and HCV infection. This warrants close monitoring of kidney function during screening and follow-up. Patients with CKD should be screened for viral hepatitis.

Download full-text PDF

Source
http://dx.doi.org/10.4103/1319-2442.388189DOI Listing

Publication Analysis

Top Keywords

chronic kidney
8
kidney disease
8
hepatitis virus
8
hbv hcv
8
112 chronic
8
hepatitis
4
hepatitis status
4
status progression
4
chronic
4
progression chronic
4

Similar Publications

Importance: Gestational exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of adverse fetal kidney outcomes. However, details regarding timing, specific NSAIDs, and long-term childhood kidney outcomes are limited.

Objective: To evaluate the association between gestational exposure to NSAIDs and the risk of chronic kidney disease (CKD) in childhood.

View Article and Find Full Text PDF

Risk of acute kidney injury after contrast-enhanced MRI examinations in a pediatric population.

Eur Radiol

December 2024

Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Objectives: To investigate the associations between gadolinium-based contrast agent (GBCA) administration and the occurrence of acute kidney injury (AKI) in pediatric patients, and to determine the risks associated with AKI.

Materials And Methods: This retrospective study was conducted on pediatric patients who underwent contrast-enhanced or unenhanced MRI between January 1st, 2015, and June 30th, 2021. Examinations were included if they had data on height and serum creatinine levels within 3 months before and 2 days after the examinations.

View Article and Find Full Text PDF

Mineralocorticoid receptor antagonists (MRAs) represent one of the cornerstones of treatment for heart failure with reduced ejection fraction. Post-hoc data from the TOPCAT trial, conducted in patients with heart failure mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), suggest the possible clinical benefit of MRAs, particularly for slightly reduced ejection fraction values. The advent of non-steroidal MRAs, including finerenone, seems to represent a turning point in the treatment for HFmrEF/HFpEF.

View Article and Find Full Text PDF

Use of antibiotics in patients with chronic kidney disease: evidence from the real world.

Expert Opin Drug Saf

December 2024

Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira-Audifarma S.A, Pereira, Risaralda, Colombia.

Background: Most antibiotics require dose adjustments in patients with chronic kidney disease (CKD) to avoid accumulation and toxicity. The aim was to characterize the use of systemic antibiotics in a group of patients with CKD and to adjust the dose according to the glomerular filtration rate (GFR).

Research Design And Methods: Observational study of patients with a diagnosis of CKD who received antibiotics between January-2021 July 2022.

View Article and Find Full Text PDF

Aims: Serum creatinine and albuminuria are the core of most CKD prediction and progression risk models. Several biomarkers have been introduced to improve these results such as beta-2-microglobulin (B2M) and cystatin C (CysC). Nevertheless, few clinical comparisons of these biomarkers are available.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!